Estradiol/Norethindrone Acetate

Tier C — Watch / trade

Noven Pharmaceuticals Inc

Originator

1998

First approval

Expiry (public)

No sales data

Peak sales

Small molecule

Type

Targets：ERs, PR

Brand：Estalis, Estragest TTS, Menoaid, Combipatch, Combestril

Indications (approved)：Menopausal symptoms, Hot flushes, Vasomotor symptoms, Oestrogen deficiency syndrome, Postmenopausal osteoporosis, Vulvovaginal atrophy

Regional status

Approved

1998-08-07

No progress

2004-05-28

China

Approved

2004-11-17

Japan

Approved

2008-10-16

Factories producing this API9

Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.

9 producing factories on file — sign in to view the named list (factory details are not shown to guests).

Synthetic routes & intermediates

Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.

Frequently asked questions

What are the approved indications of Estradiol/Norethindrone Acetate?

Approved indications include: Menopausal symptoms, Hot flushes, Vasomotor symptoms, Oestrogen deficiency syndrome, Postmenopausal osteoporosis, Vulvovaginal atrophy.

When does the Estradiol/Norethindrone Acetate patent expire?

No public expiry year is available for Estradiol/Norethindrone Acetate yet; this page updates once verified.

How do I get a quote for Estradiol/Norethindrone Acetate intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-27